• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Avid Bioservices Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Regulation FD Disclosure, Financial Statements and Exhibits

    1/30/25 5:01:30 PM ET
    $CDMO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CDMO alert in real time by email
    false000070456200007045622025-01-302025-01-30

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549



    FORM 8-K



    CURRENT REPORT
    PURSUANT TO SECTION 13 OR 15(d)
    OF THE SECURITIES EXCHANGE ACT OF 1934
     
    January 30, 2025
    Date of Report
    (Date of earliest event reported)



    AVID BIOSERVICES, INC.
    (Exact name of registrant as specified in its charter)



    Commission File Number 001-32839
     
    Delaware
     
    95-3698422
     (State or other jurisdiction of incorporation or organization)    (IRS Employer Identification No.)

    14191 Myford Road
    Tustin, CA 92780
    (Address of principal executive offices, including zip code)
     
    (714) 508-6100
    (Registrant’s telephone number, including area code)
     
    (Former name or former address, if changed since last report)



    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
     
    ☐
    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
     
    ☐
    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
     
    ☐
    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
     
    ☐
    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
     
    Securities registered pursuant to Section 12(b) of the Act:
     
    Title of each class
     
    Trading Symbol(s)
     
    Name of each exchange
    on which registered
    Common Stock, par value $0.001 per share
     
    CDMO
     
    The NASDAQ Stock Market LLC

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
     
    ☐        Emerging growth company

    ☐       If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
     


    Item 5.07.
    Submission of Matters to a Vote of Security Holders.
     
    On January 30, 2025, Avid Bioservices, Inc., a Delaware corporation (the “Company”), held a special meeting of stockholders (the “Special Meeting”). As of December 11, 2024, the record date for the Special Meeting (the “Record Date”), 63,963,302 shares of the Company’s common stock, $0.001 par value per share (the “Common Stock”) were outstanding and entitled to vote at the Special Meeting. A summary of the matters voted upon by stockholders at the Special Meeting is set forth below.
     
    A total of 49,753,341 shares of Common Stock were present at the Special Meeting in person, by virtual attendance, or by proxy, which represents approximately 77.78% of the shares of Common Stock outstanding as of the Record Date.

    Proposal 1. Approval of the Merger Agreement.
     
    The Company’s stockholders approved the adoption of the Agreement and Plan of Merger, dated November 6, 2024 (the “Merger Agreement”), by and among the Company, Space Finco, Inc. (“Parent”) and Space Mergerco, Inc. (“Merger Sub”), pursuant to which Merger Sub will merge with and into the Company, and as a result of which the separate corporate existence of Merger Sub will cease, and the Company will continue as the surviving corporation and a wholly owned subsidiary of Parent (the “Merger”), and approved the Merger (“Proposal 1”). The final voting results are as follows:

    Votes For
     
    Votes Against
     
    Abstentions
    42,231,567
     
    7,267,943
     
    253,831

    Proposal 2. The Compensation Proposal.
     
    The Company’s stockholders approved, on an advisory (non-binding) basis, the compensation that may be paid or become payable to the Company’s named executive officers that is based on or otherwise relates to the Merger Agreement and the transactions contemplated by the Merger Agreement. The final voting results are as follows:

    Votes For
     
    Votes Against
     
    Abstentions
    33,910,961
     
    15,220,783
     
    621,597

    Proposal 3. The Adjournment Proposal.

    In connection with the Special Meeting, the Company also solicited proxies with respect to a proposal to approve the adjournment of the Special Meeting to a later date or dates, if necessary or appropriate, including to solicit additional proxies to approve Proposal 1 if there were insufficient votes to approve Proposal 1 at the time of the Special Meeting (“Proposal 3”). Because Proposal 1 was approved at the Special Meeting, Proposal 3 was not necessary or appropriate and was not presented for approval at the Special Meeting.

    Item 7.01.
    Regulation FD Disclosure.

    On January 30, 2025, the Company issued a press release announcing the results of the Special Meeting and that the Company anticipates that the transaction contemplated by the Merger Agreement will close in the coming days. The information contained in Exhibit 99.1 is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall it be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.
     

    Item 9.01.
    Financial Statements and Exhibits.
     
    (d) Exhibits

    Exhibit
    Number
     
    Exhibit Description
    99.1
     
    Press Release, dated as of January 30, 2025.
    104
     
    Cover Page Interactive Data File (embedded within the Inline XBRL document).
     

    SIGNATURES
     
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
     
     

    AVID BIOSERVICES, INC.

     
    By:
     /s/ Daniel R. Hart
     
    Daniel R. Hart
     
    Chief Financial Officer
       
    Date: January 30, 2025
       



    Get the next $CDMO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CDMO

    DatePrice TargetRatingAnalyst
    9/28/2023Mkt Perform
    William Blair
    3/14/2023$20.00Sector Weight → Overweight
    KeyBanc Capital Markets
    3/9/2022$31.00 → $28.00Overweight
    Stephens & Co.
    12/8/2021$29.00 → $35.00Buy
    Craig-Hallum
    12/8/2021$27.00 → $32.00Outperform
    RBC Capital
    12/8/2021Overweight → Sector Weight
    Keybanc
    6/30/2021$21.00 → $29.00Buy
    Craig-Hallum
    6/30/2021$21.00 → $27.00Outperform
    RBC Capital
    More analyst ratings

    $CDMO
    SEC Filings

    View All

    SEC Form 15-12G filed by Avid Bioservices Inc.

    15-12G - Avid Bioservices, Inc. (0000704562) (Filer)

    2/18/25 6:07:47 AM ET
    $CDMO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 POS filed by Avid Bioservices Inc.

    S-8 POS - Avid Bioservices, Inc. (0000704562) (Filer)

    2/5/25 5:13:38 PM ET
    $CDMO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 POS filed by Avid Bioservices Inc.

    S-8 POS - Avid Bioservices, Inc. (0000704562) (Filer)

    2/5/25 5:13:36 PM ET
    $CDMO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CDMO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    V. P., General Counsel Ziebell Mark R returned 66,799 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - Avid Bioservices, Inc. (0000704562) (Issuer)

    2/7/25 7:40:25 PM ET
    $CDMO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Thoma Jeanne returned 45,611 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - Avid Bioservices, Inc. (0000704562) (Issuer)

    2/7/25 7:40:10 PM ET
    $CDMO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Sargen Gregory returned 36,368 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - Avid Bioservices, Inc. (0000704562) (Issuer)

    2/7/25 7:39:57 PM ET
    $CDMO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CDMO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Avid Bioservices Launches New Company Website Designed to Boost Company Brand Awareness and Enhance the Visitor Experience

    TUSTIN, Calif., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced the launch of its new corporate website. The new site, which can be visited at www.avidbio.com, combines Avid's elevated brand story and visual identity with improved functionality and navigation, all aimed at enhancing the visitor experience, particularly for current and prospective customers. The reimagined Avid website captures the company's elevated brand throu

    2/10/25 8:05:59 AM ET
    $CDMO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Avid Bioservices, Inc. Provides Notice of Fundamental Change and Make-Whole Fundamental Change to Holders of its Convertible Notes in Connection with Completed Merger

    TUSTIN, Calif., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. ("Avid" or the "Company"), a dedicated biologics contract development and manufacturing organization ("CDMO") working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today provided notice (the "Notice") to holders of its 7.00% Convertible Senior Notes due 2029 (the "Notes"), pursuant to the terms of the Indenture, dated as of March 12, 2024 (the "Indenture"), by and between the Company and U.S. Bank Trust Company, National Association ("U.S. Bank"), as trustee, governing the Notes that, in connection with the closing of the transa

    2/5/25 10:45:00 AM ET
    $CDMO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Avid Bioservices poised for significant growth with new partners GHO Capital and Ampersand Capital Partners

    Acquisition of biologics Contract Development and Manufacturing Organisation Avid Bioservices now completedGHO and Ampersand's deep experience in CDMO investing to support Avid's next stage of rapid growth including expanded offerings, talent investment and greater geographic reach LONDON and BOSTON and TUSTIN, Calif., Feb. 05, 2025 (GLOBE NEWSWIRE) -- GHO Capital Partners LLP ("GHO"), the European specialist investor in global healthcare, and Ampersand Capital Partners ("Ampersand"), a private equity firm specialising in growth equity investments in the life sciences and healthcare sectors, today announced the successful closing of the previously announced acquisition of Avid Bioservices

    2/5/25 9:55:00 AM ET
    $CDMO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CDMO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Hancock Richard B bought $202,036 worth of shares (38,803 units at $5.21), increasing direct ownership by 49% to 117,563 units (SEC Form 4)

    4 - Avid Bioservices, Inc. (0000704562) (Issuer)

    1/10/24 7:56:02 PM ET
    $CDMO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Hancock Richard B converted options into 9,612 shares and bought $134,734 worth of shares (23,000 units at $5.86), increasing direct ownership by 71% to 78,760 units (SEC Form 4)

    4 - Avid Bioservices, Inc. (0000704562) (Issuer)

    12/18/23 7:31:12 PM ET
    $CDMO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4: Carleone Joseph bought $190,696 worth of shares (20,000 units at $9.53), increasing direct ownership by 27% to 93,956 units

    4 - Avid Bioservices, Inc. (0000704562) (Issuer)

    9/22/23 12:51:46 PM ET
    $CDMO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CDMO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    William Blair initiated coverage on Avid Bioservices

    William Blair initiated coverage of Avid Bioservices with a rating of Mkt Perform

    9/28/23 8:08:44 AM ET
    $CDMO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Avid Bioservices upgraded by KeyBanc Capital Markets with a new price target

    KeyBanc Capital Markets upgraded Avid Bioservices from Sector Weight to Overweight and set a new price target of $20.00

    3/14/23 7:17:41 AM ET
    $CDMO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Stephens & Co. reiterated coverage on Avid Bioservices with a new price target

    Stephens & Co. reiterated coverage of Avid Bioservices with a rating of Overweight and set a new price target of $28.00 from $31.00 previously

    3/9/22 6:57:34 AM ET
    $CDMO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CDMO
    Leadership Updates

    Live Leadership Updates

    View All

    Uber Technologies, Jabil and Builders FirstSource Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

    NEW YORK, Dec. 1, 2023 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, December 18, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P SmallCap 600 are more representative of the small-cap market space. The companies being removed from t

    12/1/23 6:16:00 PM ET
    $ALK
    $ALKS
    $AWI
    Air Freight/Delivery Services
    Consumer Discretionary
    Biotechnology: Pharmaceutical Preparations
    Health Care

    STERIS Appoints Esther M. Alegria, Ph.D. to Board of Directors

    DUBLIN, IRELAND, May 03, 2023 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") announced today that Esther M. Alegria, Ph.D. has been elected to the Board of Directors, effective today. "We are pleased to welcome Dr. Alegria to our Board," said Mohsen Sohi, Chairman of STERIS. "She brings over three decades of experience in the biopharmaceuticals industry to our Board and will be a valuable addition." Dr. Alegria is the Founder and Chief Executive Officer of APIE Therapeutics, where she leads a team focused on the development of therapeutic drugs to treat chronic and debilitating diseases. Prior to APIE, Dr. Alegria was President and Senior Executive Advisor at Catal

    5/3/23 4:30:00 PM ET
    $CDMO
    $STE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Industrial Specialties

    Avid Bioservices Appoints Oksana Lukash as Vice President, People

    TUSTIN, Calif., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced the appointment of Oksana Lukash, as vice president, people. Ms. Lukash has more than 20 years of human resources experience with both established and entrepreneurial organizations across a range of industries. Prior to joining Avid, Ms. Lukash served as vice president, people & culture at Oncocyte Corporation, a precision diagnostics company. During her three year

    11/16/22 8:05:00 AM ET
    $CDMO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CDMO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Avid Bioservices Inc.

    SC 13G - Avid Bioservices, Inc. (0000704562) (Subject)

    12/13/24 10:53:25 AM ET
    $CDMO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Avid Bioservices Inc.

    SC 13G/A - Avid Bioservices, Inc. (0000704562) (Subject)

    11/14/24 7:53:01 PM ET
    $CDMO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Avid Bioservices Inc.

    SC 13G/A - Avid Bioservices, Inc. (0000704562) (Subject)

    11/12/24 4:15:31 PM ET
    $CDMO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CDMO
    Financials

    Live finance-specific insights

    View All

    Avid Bioservices Reports Financial Results for Second Quarter Ended October 31, 2024

    TUSTIN, Calif., Dec. 10, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced financial results for the second quarter and six months ended October 31, 2024. Highlights from the Quarter Ended October 31, 2024: "We delivered solid results in a competitive environment, with increased revenues and backlog offset by increased costs," stated Nick Green, president and CEO of Avid Bioservices. "We are pleased to reach the separately announced agre

    12/10/24 4:05:23 PM ET
    $CDMO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Avid Bioservices Reports Financial Results for First Quarter Ended July 31, 2024

    -- Recorded First Quarter Revenue of $40.2 Million -- -- Signed $66 Million in Net New Business, Resulting in Backlog of $219 Million -- -- Maintained FY2025 Revenue Guidance of Between $160 Million and $168 Million -- TUSTIN, Calif., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced financial results for the first quarter ended July 31, 2024. Highlights from the Quarter Ended July 31, 2024, and Other Events:

    9/9/24 4:05:31 PM ET
    $CDMO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Avid Bioservices to Report Financial Results for First Quarter of Fiscal Year 2025 After Market Close on September 9, 2024

    TUSTIN, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality services to biotechnology and pharmaceutical companies, today announced that it will report financial results for the first quarter of fiscal year 2025 on September 9, 2024, after market close and will host a webcast at 1:30 PM Pacific Time (4:30 PM Eastern Time). Members of Avid's senior management will discuss financial results for the first quarter and review recent corporate developments. To listen to the live webcast, or access the archived webcast, please

    9/3/24 4:05:20 PM ET
    $CDMO
    Biotechnology: Pharmaceutical Preparations
    Health Care